In the trial, researchers randomised 4,174 patients to receive extended-release metoprolol succinate and 4,177 patients to receive placebo starting two to four hours before surgery and continuing for 30 days after surgery.
They found that fewer patients in the metoprolol group (176) than in the placebo group (239) suffered a heart attack, indicating that patients receiving metoprolol were 27 percent less likely to suffer a heart attack.
However, the trial also showed that 29 metoprolol patients as compared to 97 placebo patients died, indicating that patients receiving metoprolol were 33 percent more likely to die.
Researchers also found that 41 metoprolol patients versus 19 placebo patients suffered a stroke, indicating that patients receiving metoprolol had more than double the risk of a stroke.
Considering the heart attacks less than one-third of these patients also had a complication of their heart attack like heart failure.
On contrary, more than half of the patients who suffered a stroke were left incapacitated or needing help with everyday activities.
Analysis of the data suggested that metoprolol increased the risk of death and stroke by increasing the risk of the low blood pressures that required treatment.
"Considering these results, patients are unlikely to accept the risks associated with perioperative metoprolol seen in POISE," said Dr. Gordon Guyatt, POISE outcome adjudication committee chair, McMaster University, Hamilton, Canada.
The study will be published online by the prestigious medical journal, The Lancet.
Source-ANI
RAS/L